Omega-3 Fatty Acids (EPA/DHA) ： Autoimmune Conditions
BThe VITAL trial showed a 15% reduction in autoimmune disease risk with omega-3 supplementation. Additional clinical trials demonstrate benefits for supporting balanced inflammatory responses in rheumatoid arthritis and inflammatory bowel disease.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'immunecited.com';
const params = 'ingredient\u003Domega\u002D3\u0026condition\u003Dautoimmune\u002Dconditions';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
結論
The VITAL trial showed a 15% reduction in autoimmune disease risk with omega-3 supplementation. Additional clinical trials demonstrate benefits for supporting balanced inflammatory responses in rheumatoid arthritis and inflammatory bowel disease.
Key Study Findings
Review
Impact of Nutritional Diet Therapy on Rheumatoid Arthritis Disease Activity.
Dose: None
vs: None
Outcome: rheumatoid arthritis disease activity modulation through diet
効果: None
None
対象集団: patients with rheumatoid arthritis
Case Reports
n=1
GPIHBP1 Autoantibody-Related Hypertriglyceridemia in a 12-Year-Old Girl With Systemic Lupus Erythematosus.
Dose: None
vs: None
Outcome: GPIHBP1 autoantibody and LPL mass normalization
効果: None
None
対象集団: 12-year-old girl with SLE and severe hypertriglyceridemia
Review
Epigenetic and Mitochondrial Metabolic Dysfunction in Multiple Sclerosis: A Review of Herbal Drug Approaches and …
Dose: None
vs: None
Outcome: Epigenetic and mitochondrial modulation in MS
効果: None
None
対象集団: Multiple sclerosis patients (review)
Review
The Role of Nutrition in the Development, Management, and Prevention of Rheumatoid Arthritis: A Comprehensive …
Dose: None
vs: None
Outcome: RA risk and disease activity
効果: None
None
対象集団: Patients with rheumatoid arthritis
Review
Specialized pro-resolving mediators and autoimmunity: Recent insights and future perspectives.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: None
Systematic Review
Modulating inflammation and oxidative stress in rheumatoid arthritis: a systematic review of nutraceutical interventions.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: Systematic review of nutraceuticals in rheumatoid arthritis
Key Statistics
10
研究数
25000
参加者数
↑
Positive
B
グレード
Referenced Papers
Case reports in …
2026
Nutrients
2026
Inflammopharmacology
2025
26 件の引用
Specialized pro-resolving mediators and autoimmunity: Recent insights and future perspectives.
Review
Autoimmunity reviews
2025
10 件の引用
Molecular neurobiology
2025
6 件の引用
Modulating inflammation and oxidative stress in rheumatoid arthritis: a systematic review of nutraceutical interventions.
Systematic Review
Inflammopharmacology
2025
1 件の引用
Nutrients
2025
Critical reviews in …
2024
25 件の引用
Autoimmunity reviews
2024
12 件の引用
The Interconnection Between Systemic Lupus Erythematosus and Diet: Unmet Needs, Available Evidence, and Guidance-A Patient-Driven, Multistep-Approach Study.
Systematic Review
Nutrients
2024
2 件の引用
European review for …
2023
67 件の引用
Nutrients
2022
29 件の引用
BMJ (Clinical research …
2022
9 件の引用
Journal of medicinal …
2022
8 件の引用
Nederlands tijdschrift voor …
2022
1 件の引用
Effect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: a systematic review.
Systematic Review
Nutritional neuroscience
2021
82 件の引用
Clinical science (London, …
2021
35 件の引用
Microbiology and immunology
2020
8 件の引用
Current rheumatology reviews
2019
40 件の引用
FEBS open bio
2016
1 件の引用
Environmental health perspectives
2015
72 件の引用
Medical hypotheses
2014
36 件の引用
Current diabetes reports
2010
33 件の引用
Journal of the …
2010
11 件の引用
Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Fas(lpr) mice by N-3 fatty acids.
Other
Journal of the …
2005
64 件の引用
Current opinion in …
2005
26 件の引用
Current atherosclerosis reports
2004
464 件の引用
Journal of the …
2002
2016 件の引用
Age
1998
4 件の引用
Biochemical Society transactions
1995
15 件の引用
Journal of immunology …
1994
119 件の引用
World review of …
1994
8 件の引用
The American journal …
1991
2278 件の引用
Rheumatic diseases clinics …
1991
19 件の引用
Proceedings of the …
1990
49 件の引用
The American journal …
1987
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 250-500 mg combined EPA/DHA/day
- antiinflammatory:
- 1,000-3,000 mg combined EPA/DHA/day
上限量： 3,000 mg/day EPA+DHA (FDA-recognized as safe)
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Positive | 1 |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Neutral | -- |
推奨摂取タイミング： With meals
Safety & Side Effects
報告されている副作用
- ⚠ Fishy aftertaste and burping
- ⚠ Gastrointestinal discomfort (nausea, diarrhea)
- ⚠ Increased bleeding risk at high doses
- ⚠ Potential LDL cholesterol increase at very high doses
既知の相互作用
- ● Anticoagulants and antiplatelet drugs (may increase bleeding risk)
- ● Blood pressure medications (additive blood pressure lowering)
- ● Orlistat (may reduce omega-3 absorption)
- ● Cyclosporine (may modify immunosuppressive effects)
耐容上限摂取量： 3,000 mg/day EPA+DHA (FDA-recognized as safe)
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Omega-3 Fatty Acids (EPA/DHA) help with Autoimmune Conditions?
Based on 10 studies with 25,000 participants, there is moderate evidence from clinical studies that Omega-3 Fatty Acids (EPA/DHA) may support Autoimmune Conditions management. Our evidence grade is B (Good Evidence).
How much Omega-3 Fatty Acids (EPA/DHA) should I take for Autoimmune Conditions?
Studies have used various dosages. A commonly studied range is 250-500 mg combined EPA/DHA/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (EPA/DHA)?
Reported side effects may include Fishy aftertaste and burping, Gastrointestinal discomfort (nausea, diarrhea), Increased bleeding risk at high doses, Potential LDL cholesterol increase at very high doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (EPA/DHA) and Autoimmune Conditions?
We rate the evidence as Grade B (Good Evidence). This rating is based on 10 peer-reviewed studies with 25,000 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Autoimmune Conditions
Omega-3 Fatty Acids (EPA/DHA) 他の症状・状態について
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。